In The News: Department of Brain Health
A new program at UNLV is addressing a critical healthcare shortage in the Las Vegas valley.
The occupational therapists in training at UNLV will one day work with people recovering from strokes, injury — and COVID-19.
Picture of UNLV School of Integrated Health Sciences students working on mobility training practices with infant dolls at the Occupational Therapy lab facility at the Shadow Lane campus.
Resverlogix Corp., a world leader in epigenetics, or gene regulation, announces today new data that demonstrates their first-in-class oral small molecule BET inhibitor candidate Apabetalone significantly improves cognition and reduces cognitive decline among high-risk patients with cardiovascular disease and diabetes mellitus.
UNLV launched new Occupational Therapy program that trains students in a home instead of a classroom or lab.
Mary Ashley Galan-Gornal grasped the adaptive knife in her right hand, placed the red delicious apple securely in the vise, and sliced off a piece of the fruit.
Approval of aducanumab will herald a new era in Alzheimer’s disease care and research.
The Food and Drug Administration’s controversial June 7 approval of aducanumab (Aduhelm) means that for the first time in 18 years, Alzheimer’s patients have a new treatment option.
NervGen Pharma Corp., a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced yesterday it has entered into a research collaboration with Dr. Ksenia Kastanenka of Massachusetts General Hospital (MGH) to study the effects of NervGen’s lead compound, NVG-291, in validated animal models of Alzheimer’s disease.
NervGen Pharma Corp., a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced today it has entered into a research collaboration with Dr. Ksenia Kastanenka of Massachusetts General Hospital (MGH) to study the effects of NervGen's lead compound, NVG-291, in validated animal models of Alzheimer's disease.
The Food and Drug Administration’s approval of Biogen and Eisai’s anti-amyloid antibody aducanumab on June 7 left many questions unanswered, including how to use the drug in clinical practice.